Keywords: Pfizer, Rolling submission, Crizotinib, USA, FDA, Germany, VAT evasion, Axitinib, Bosutinib
Pfizer commences rolling FDA submission for lung cancer drug crizotinib; denies German VAT evasion
Article | 17 January 2011
Global pharma behemoth Pfizer (NYSE: PFE) last week started a rolling submission for a New Drug Application to the US ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- US Supreme Court says patent settlement can "sometimes" be illegal
- InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
- Additional indications in Japan for Roche's Avastin and Astellas' Prograf
- Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
